Physician profile
Charles E Neetz
NPI 1215489513
$4,576.57
in general payments reported to CMS, 2019-2025
26 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $290 · 2022: $994 · 2023: $1,295 · 2024: $1,499 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,091.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $691.10 | 2021-2023 | |
| Amgen INC. | $382.93 | 2021-2024 | Evenity, Repatha, Otezla |
| Ibsa Pharma INC. | $375.00 | 2023-2024 | Tirosint |
| Janssen Pharmaceuticals, INC | $337.07 | 2022-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $215.13 | 2022-2024 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $197.20 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $172.57 | 2023-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $132.29 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $127.92 | 2022-2023 | Recorlev |
| Corcept Therapeutics | $125.56 | 2025 | Korlym |
| Exeltis, USA INC. | $125.00 | 2025 | |
| Pharming Healthcare, INC. | $124.99 | 2024 | Ruconest |
| Pfizer INC. | $99.83 | 2021-2024 | |
| Exact Sciences Corporation | $68.80 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $67.58 | 2023-2024 | Freestyle Libre 3 |
| Kerecis Limited | $41.29 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Daiichi Sankyo INC. | $38.27 | 2022 | |
| Merck Sharp & Dohme LLC | $29.90 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.82 | 2022 | |
| Biogen, INC. | $27.90 | 2023 | Skyclarys |
| Otsuka America Pharmaceutical, INC. | $16.80 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $16.74 | 2021 | |
| Genzyme Corporation | $14.97 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.28 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Neetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.